Gadoxetate Disodium Dosage

Medically reviewed by Drugs.com. Last updated on Jul 14, 2023.

Applies to the following strengths: 181.43 mg/mL

Usual Adult Dose for:

Liver Magnetic Resonance Imaging

Additional dosage information:

Renal Dose Adjustments
Liver Dose Adjustments
Precautions
Dialysis

Usual Adult Dose for Liver Magnetic Resonance Imaging

0.1 mL/kg body weight(0.025 mmol/kg body weight) administered undiluted as a single intravenous bolus injection at a flow rate of approximately 2 mL/second.

Renal Dose Adjustments

Gadolinium based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73 m2), or acute renal insufficiency of any severity due to the hepatorenal syndrome or in the perioperative liver transplantation period. In these patients, avoid use of gadolinium based contrast agents unless the diagnostic information is essential and not available with noncontractile enhanced magnetic resonance imaging (MRI).

Liver Dose Adjustments

A dose adjustment is not necessary for patients with hepatic impairment.

Precautions

US BOXED WARNING:

NEPHROGENIC SYSTEMIC FIBROSIS (NSF): Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in such patients unless the diagnostic information is essential and not available with noncontrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle, and internal organs. The risk for NSF appears to be highest among patients with chronic, severe kidney disease (GFR less than 30 mL/min/1.73 m2) or acute kidney injury. Patients should be screened for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g., greater than 60 years of age, hypertension, or diabetes), estimate the GFR through laboratory testing. For patients at highest risk for NSF, do not exceed the recommended dose and allow a sufficient period of time for elimination of the drug from the body prior to any readministration.

Adequate and well-controlled studies in pediatric patients have not been conducted; safety and efficacy have not been established in premature infants.

Consult WARNINGS section for additional precautions.